Why Acadia Pharmaceuticals Fell Even As Profit Rose

Acadia Pharmaceuticals just watched the European Commission sign off on DAYBU for Rett syndrome, a milestone that would have sounded like pure upside back in January. Investors who held Acadia Pharmaceuticals from the start of the year are down 24.9%, including dividends. If you had put fresh capital to work on 1 January, you would now be asking a blunt question: with setbacks in remlifanserin and progress in DAYBU, which side of Acadia’s business should matter more for you now?

A Narrative on Simply Wall St is one investor's written case for a company, with its growth, margin and multiple assumptions spelled out. Those assumptions imply an estimated Fair Value.

Acadia Pharmaceuticals has already moved. See which of 29 high quality undervalued stocks still trade below our estimates.

The Two Acadia Pharmaceuticals Stories Investors Had To Weigh

The shares cost US$26.71 at the start of the period, and anyone looking at Acadia Pharmaceuticals then had to pick between two very different stories.

The bullish narrative put fair value at US$29.32, assuming revenue growth of 11.2% a year and a future P/E of 21.2x, supported by nine disclosed programs that could reduce reliance on a single treatment.

The bearish view set fair value at US$15.83 and focused on Medicare price negotiations after 2029 and heavy dependence on NUPLAZID and DAYBUE as key risks to future revenue and margins.

What The Results Changed For Acadia Pharmaceuticals

Acadia Pharmaceuticals secured European Commission approval for DAYBU in Rett syndrome, which supported the optimistic story about broadening the product base. Measured results added some support, with Q2 2026 revenue at US$307.959m and net income at US$31.5m, both above Q2 2025, and net margin at 10.2%. The remlifanserin Phase 2 miss for Alzheimer’s psychosis challenged that enthusiasm, so the evidence cut both ways.

The key assumption was that DAYBU and NUPLAZID would offset pipeline risk. When you look at another drug developer, test that same claim against segment revenue, absolute profit and net margin in each new quarterly report.

What You Would Be Paying For In Acadia Pharmaceuticals Today

Acadia Pharmaceuticals now trades at US$19.74, leaving investors who held from the start of the year with a 24.9% loss. The selected Narrative’s Fair Value sits above the current price and leans on DAYBUE and NUPLAZID execution plus a still-viable remlifanserin path.

To close that gap, a buyer today would need to assume DAYBUE and NUPLAZID can sustain meaningful revenue and margin contribution while remlifanserin progresses through Phase 3 on the timetable analysts model.

"Current numbers and management targets, including roughly US$1.7b in potential 2028 net sales from DAYBUE and NUPLAZID and an estimated US$11b unadjusted global peak opportunity across the pipeline, imply the share price reflects significant skepticism around both the durability of existing brands and the probability of success for remlifanserin."

That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for

Before The Next Story Makes Headlines

This company's disappointment is already part of the story. Your next idea could come from looking where the price and the possibilities still seem far apart. Here are three companies priced below our estimates.

• Company 1 - 48% below our estimate - turns a record backlog of tech-heavy construction projects into recurring work.
• Company 2 - 22% below our estimate - embeds AI tools into established enterprise cloud, productivity, developer and security workflows.
• Company 3 - 37% below our estimate - tackles complex AI failure, safety and regulatory challenges with multidisciplinary science consulting.

Three companies from the same screener. Open every one of the 24 solid balance sheet companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com